Prognostic Factors of Low-Grade Gliomas in Adults.
Mariana DeacuSteliana PopescuAny Docu AxeleradTheodor Sebastian TopliceanuMariana AschieMadalina BosoteanuGeorgeta Camelia CozaruAna Maria CretuRaluca Ioana VodaCristian Ionuț OrasanuPublished in: Current oncology (Toronto, Ont.) (2022)
Adult low-grade gliomas are a rare and aggressive pathology of the central nervous system. Some of their characteristics contribute to the patient's life expectancy and to their management. This study aimed to characterize and identify the main prognostic factors of low-grade gliomas. The six-year retrospective study statistically analyzed the demographic, imaging, and morphogenetic characteristics of the patient group through appropriate parameters. Immunohistochemical tests were performed: IDH1, Ki-67, p53, and Nestin, as well as FISH tests on the CDKN2A gene and 1p/19q codeletion. The pathology was prevalent in females, with patients having an average age of 56.31 years. The average tumor volume was 41.61 cm 3 , producing a midline shift with an average of 7.5 mm. Its displacement had a negative impact on survival. The presence of a residual tumor resulted in decreased survival and is an independent risk factor for mortality. Positivity for p53 identified a low survival rate. CDKN2A mutations were an independent risk factor for mortality. We identified that a negative prognosis is influenced by the association of epilepsy with headache, tumor volume, and immunoreactivity to IDH1 and p53. Independent factors associated with mortality were midline shift, presence of tumor residue, and CDKN2A gene deletions and amplifications.
Keyphrases
- low grade
- high grade
- prognostic factors
- cardiovascular events
- end stage renal disease
- case report
- risk factors
- copy number
- ejection fraction
- type diabetes
- squamous cell carcinoma
- chronic kidney disease
- high resolution
- gene expression
- cardiovascular disease
- mass spectrometry
- dna methylation
- neoadjuvant chemotherapy
- young adults
- genome wide identification
- rectal cancer
- locally advanced
- fluorescence imaging